Endoscopic Ultrasound-Guided Ethanol Ablation for Aldosterone-Producing Adenoma

NCT07700472 | Not Yet Recruiting DMC

• 1 other identifier: 2026-0558-01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, single-center, single-arm study evaluating endoscopic ultrasound-guided ethanol ablation for left-sided aldosterone-producing adenoma. Eligible participants will receive the ablation procedure and be followed for safety, imaging response, biochemical remission, and clinical remission. The study is expected to enroll 30 participants.

Conditions

Primary Aldosteronism; Aldosterone-Producing Adenoma

Keywords

Endoscopic ultrasound; Ethanol ablation; Aldosterone-producing adenoma; EUS-guided ethanol ablation; Primary aldosteronism

Outcome Measures

Primary Outcomes (1)

• Procedure-related major adverse events

  Assessment of predefined procedure-related major adverse events occurring within 24-48 hours after endoscopic ultrasound-guided ethanol ablation, including imaging-confirmed major bleeding, gastrointestinal perforation, major organ infarction, and hypertensive urgency or emergency (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHg).

  Within 24-48 hours after endoscopic ultrasound-guided ethanol ablation

Secondary Outcomes (3)

• Complete tumor ablation on imaging

  6 months after endoscopic ultrasound-guided ethanol ablation

• Complete biochemical remission rate

  6 months after endoscopic ultrasound-guided ethanol ablation

• Complete clinical remission rate

  6 months after endoscopic ultrasound-guided ethanol ablation

Study Arms (1)

Endoscopic Ultrasound-Guided Ethanol Ablation

EXPERIMENTAL

Participants with left-sided unilateral aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance.

Procedure: Endoscopic Ultrasound-Guided Ethanol Ablation

Interventions

Endoscopic Ultrasound-Guided Ethanol Ablation PROCEDURE

Participants with left-sided aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance.

Endoscopic Ultrasound-Guided Ethanol Ablation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of left-sided aldosterone-producing adrenal adenoma.
• Unwillingness to undergo adrenalectomy or presence of contraindications to surgery.
• Ability and willingness to provide written informed consent.

You may not qualify if:

• History of alcohol allergy.
• Inability to discontinue beta-blockers.
• Inability to discontinue anticoagulants, antiplatelet agents, or glucocorticoids.
• Platelet count \<50 × 10\^9/L or uncorrectable coagulation dysfunction.
• Imaging findings suggestive of adrenal cyst, adrenal hematoma, or myelolipoma.
• Presence of other active malignancies.
• Pregnancy or breastfeeding; alcohol abuse; drug abuse; or mental disorder that may interfere with study participation.
• Severe comorbid conditions, including any of the following: New York Heart Association (NYHA) class III-IV heart failure or hospitalization for worsening chronic heart failure within the previous 3 months; stroke or acute coronary syndrome within the previous 3 months; severe anemia (hemoglobin \<60 g/L); severe hepatic disease (alanine aminotransferase ≥3 × the upper limit of normal); severe renal disease requiring dialysis or estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m²; systemic inflammatory response syndrome (SIRS); poorly controlled diabetes mellitus (fasting blood glucose ≥13.3 mmol/L); severe obesity (body mass index ≥35 kg/m²); untreated aneurysm; or any other severe medical condition that may interfere with treatment or study follow-up.
• Poor compliance or any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.

Sponsors & Collaborators

• Chongqing Medical University: lead

Study Sites (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Choongqing, 400016, China

Location

Related Publications (1)

• Deng L, Hao Y, Zhang X, Li Q, Hu J, Yang S. Endoscopic ultrasound-guided ethanol ablation for aldosterone-producing adenoma. Endoscopy. 2026 Jun;58(S 02):E702-E703. doi: 10.1055/a-2875-0099. Epub 2026 Jun 11. No abstract available.

  PMID: 42276127 RESULT

Related Links

• Related Info

MeSH Terms

Conditions

Hyperaldosteronism; Adrenocortical Adenoma

Condition Hierarchy (Ancestors)

Adrenocortical Hyperfunction; Adrenal Gland Diseases; Endocrine System Diseases; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Adrenal Cortex Diseases

Study Officials

• Shumin Yang, MD, PhD

  First Affiliated Hospital of Chongqing Medical University

  PRINCIPAL INVESTIGATOR

• Liang Deng, MD, PhD

  First Affiliated Hospital of Chongqing Medical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Shumin Yang, MD, PhD

CONTACT

+86-023-89011552; ysm@hospital.cqmu.edu.cn

Liang Deng, MD, PhD

CONTACT

+86-023-89011510; dengliang@hospital.cqmu.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 9, 2026
• First Posted: July 14, 2026
• Study Start: July 15, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): July 15, 2029
• Last Updated: July 14, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)